Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bifeprunox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 19/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 19/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bifeprunox SCHEMBL1248663 | 0.93 | HTR1A (0.86) | HTR1ADRD2DRD4 | |
| SCHEMBL3862596 | 0.92 | DRD2 (0.85) | HTR1ADRD2DRD4 | |
| SCHEMBL1886859 | 0.92 | DRD2 (0.84) | HTR1ADRD2 | |
| SCHEMBL13533047 | 0.92 | DRD2 (1.00) | HTR1ADRD2DRD4 | |
| Bifeprunox SCHEMBL13324077 | 0.89 | DRD2 (0.80) | HTR1ADRD2 | |
| SCHEMBL12672777 | 0.89 | DRD2 (0.80) | HTR1ADRD2 | |
| Bifeprunox SCHEMBL13324126 | 0.88 | DRD2 (0.78) | HTR1ADRD2 | |
| SCHEMBL12672775 | 0.88 | DRD2 (0.82) | HTR1ADRD2 | |
| SCHEMBL1886496 | 0.86 | DRD2 (0.74) | HTR1ADRD2 | |
| SCHEMBL3859594 | 0.85 | DRD2 (0.74) | HTR1ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3774 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250295671-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2025-09-25 | — | — | US | claimed |
| US-12357642-B2 | Hazardous agent injection system | ANTARES PHARMA, INC. (US) | 2025-07-15 | — | — | US | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025080415-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | ALTO NEUROSCIENCE, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250120957-A1 | TREATMENT OF NEUROPSYCHIATRIC DISORDERS WITH TILIVAPRAM | ALTO NEUROSCIENCE, INC. | 2025-04-17 | — | — | US | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| US-20050215571-A1 | Therapeutic combination for cognititon enhancement and psychotic disorders | PFIZER INC. | 2005-09-29 | — | — | US | claimed |
| US-20050203130-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | PHARMANEUROBOOST N.V. (BE) | 2005-09-15 | — | — | US | claimed |
| US-6929801-B2 | Transdermal delivery of antiparkinson agents | ACRUX DDS PTY LTD (AU) | 2005-08-16 | — | — | US | claimed |
| WO-2005063296-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| WO-2005053796-A1 | USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS | B & B BEHEER NV (BE) | 2005-06-16 | — | — | WO | claimed |
| EP-1541197-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | B&B Beheer NV (BE) | 2005-06-15 | — | — | EP | claimed |
| CN-1198605-C | Compound with 5-HT1A activity useful for treating disorders of outer retina | ALCON UNIVERSAL LTD (CH) | 2005-04-27 | — | — | CN | claimed |
| WO-2005016898-A2 | STABLE POLYMORPH OF BIFEPRUNOX MESILATE | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-24 | — | — | WO | claimed |
| US-20040013620-A1 | Transdermal delivery of antiparkinson agents | MONASH UNIVERSITY | 2004-01-22 | — | — | US | claimed |